

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT PURSUANT TO RULE 13.09(2)(a) OF THE LISTING RULES

This announcement is made by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “**Company**” and its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

References are made to the announcements made by the Company dated 28 December 2012, 3 January 2013, 6 May 2013 and 28 June 2013 (the “**Announcements**”) pursuant to which, among other things, the Company was informed that each of Prime United Industries and China Pharmaceutical, as Vendors and as substantial shareholders of the Company, had entered into an Agreement with Sichuan Kelun Pharmaceutical Co., Ltd., as Purchaser, respectively, pursuant to which each of Prime United Industries and China Pharmaceuticals has agreed to sell to the Purchaser 180,000,000 shares and 180,000,000 shares of the Company at HK\$2.9167 per share (representing approximately 6.14% and 6.14% of the issued share capital of the Company respectively as at the date of this announcement). Capitalised terms not otherwise defined in this announcement shall have the same meaning as in the Announcements.

The Company was informed by each of Prime United Industries and China Pharmaceutical that they were informed by the Purchaser that on 2 August 2013, the Purchaser, which is a company listed on the Shenzhen Stock Exchange (stock code: 002422), issued an announcement regarding the Agreements, which stated that the Purchaser has recently obtained the approval from the Ministry of Commerce of the People’s Republic of China (商合批【2013】No. 539) to proceed with the Disposal (the “**Approval**”).

Notwithstanding, the Purchaser has informed Prime United Industries and China Pharmaceutical that, apart from the Approval, the Disposal is still under the process of approval by other relevant regulatory authorities in or outside of China in accordance with the relevant domestic provisions of China. The conditions precedent to completion of the sale and purchase of Shares pursuant to the Agreements have therefore not been satisfied as at the date of this announcement.

The Company will make further announcement upon completion of the sale and purchase of Shares pursuant to the Agreements.

As the conditions precedent may or may not be fulfilled, shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 2 August 2013

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

The directors of the Company jointly and severally accept full responsibility for accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.